Neuphoria Therapeutics Inc.
NEUP · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $24 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | $23 | -$1 | -$1 | $0 |
| % Margin | 95.8% | – | – | 0% |
| R&D Expenses | $14 | $14 | $13 | $17 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $12 | $8 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $26 | $22 | $28 |
| Operating Income | -$2 | -$27 | -$22 | -$29 |
| % Margin | -7.2% | – | – | -10,292% |
| Other Income/Exp. Net | $0 | $3 | $0 | -$1 |
| Pre-Tax Income | -$1 | -$23 | -$22 | -$29 |
| Tax Expense | -$1 | -$0 | -$1 | -$6 |
| Net Income | -$1 | -$23 | -$22 | -$23 |
| % Margin | -2.4% | – | – | -8,253.6% |
| EPS | -0.23 | -0.1 | -0.17 | -0.13 |
| % Growth | -130% | 41.2% | -30.8% | – |
| EPS Diluted | -0.23 | -0.1 | -0.17 | -0.13 |
| Weighted Avg Shares Out | 2 | 150 | 122 | 113 |
| Weighted Avg Shares Out Dil | 2 | 150 | 122 | 113 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$0 | -$22 | -$22 | -$28 |
| % Margin | -1.1% | – | – | -10,085.7% |